<DOC>
	<DOCNO>NCT02205489</DOCNO>
	<brief_summary>Primary Objective : To assess distribution IARs severity grade LEMTRADA administer RRMS patient medicate accord specify algorithm design manage infusion associate reaction .</brief_summary>
	<brief_title>Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA</brief_title>
	<detailed_description>The total duration participation study per patient approximately 13.5 month . After end second course LEMTRADA treatment , patient follow physician regular healthcare set 48 month safety monitoring period complete .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : Adult RRMS patient initiate treatment Lemtrada accord local approve label . Signed write informed consent . Exclusion criterion : Previously treat LEMTRADA . Contraindications LEMTRADA accord labeling country . Any known contraindication symptomatic therapy use infusion management guidance base local approve label . Currently participate another investigational interventional study . Any technical/administrative reason make impossible enroll patient study . Patient Investigator Subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol . Patient withdrawn consent enrollment ( start sign informed consent form ) . Despite screen patient , enrolment stop study level . Woman childbearing potential protect highlyeffective method ( ) birth control ( defined local protocol amendment case specific local requirement ) and/or unwilling unable test pregnancy . Pregnancy ( define positive beta human chorionic gonadotropin ( Î²HCG ) blood test ) , breast feed . Known infection latent tuberculosis active tuberculosis . Known infection Hepatitis B , Hepatitis C. The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>